Injectable hydrogels as matrix to retain microparticles for controlled delivery of anti-VEGF proteins for ocular applications
Wet age-related macular degeneration (AMD) or diabetic macular edema (DME) are potentially retinal diseases and they are treated by monthly or bimonthly intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents such as aflibercept (Eylea®) and ranibizumab (Lucentis®). Because...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Final Year Project (FYP) |
| Language: | English |
| Published: |
2017
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10356/70120 |